Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyrin domain-containing protein 1 (PYDC1) is a cytosolic adaptor protein that contains only a pyrin domain, distinguishing it from multi-domain inflammasome components[1][3]. It primarily acts as a negative regulator of innate immune signaling by interacting with inflammasome adaptor ASC (PYCARD) and other pyrin domain-containing proteins. Through these interactions, PYDC1 inhibits the activation of NF-κB and pro-caspase-1, resulting in decreased production of pro-inflammatory cytokines such as interleukin-1 beta and suppression of macrophage and granulocyte inflammatory responses[1][3][4]. It is generally considered a cellular checkpoint that limits excessive inflammasome activity and inflammation. No current drugs specifically target PYDC1, and it is not considered a direct therapeutic target, but its role in immune regulation could make it a subject of future research in inflammatory and autoimmune disorders[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyrin domain-containing protein 1 (PYDC1).